secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2022-01-28T23:59:59+00:00
Accession:  0001104659-22-008977
Event type: other
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex amends bylaws to implement proxy access for shareholders
----------------------------------------------------------------

- Board approved proxy access on Jan 25, 2022, adding Article III Section 13 to bylaws.
- Stockholders or group owning at least 3% of stock continuously for 3 years may nominate directors.
- Maximum nominees is greater of 2 individuals or 20% of board, subject to requirements.
- Proxy access will first apply for the 2023 annual meeting of shareholders.
- Full amendment text filed as Exhibit 3.1 to this 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000110465922008977/0001104659-22-008977-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000110465922008977/tm224432d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-008977

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer